Farmas USA

No me extraña, menudo pelotazo habéis pegado. Enhorabuena a los premiados.

Yo voy a recuperar lo de Nvax a base de chicharros...in Eleuterio and the Sniper I trust

Hola, Draghinibal, bienvenido al hilo.

Creo no te estoy entendiendo bien. Las posiciones vendedoras suelen ser iguales, no mayores,que las compradoras. (De hecho han de serlo) Creo que confundes posición vendedora con Put.

Una opción necesita de dos "contratantes" , el que vende y el que compra la opción. Sin mas.
Solo hablas de vender, pero tambien interviene en la ecuación el comprador. Y si hay un contrato negociado, es que hay dos partes, cada uno tendrá su objetivo.

Ahora te pregunto lo siguiente. Es un ejemplo ficticio. Tengo una acción, que cotiza ahora mismo a 10. Voy a comprar una call a 20 y comprar una putt a 5. Ala. Estoy cubierto. ¿Soy bajista o alcista?. Y claro, alguien me las ha vendido. El que vende la put.... es bajista? Puede. Pero tambien puede ser que quera comprarla a 5 y mientras gane perras mediante ventas de opciones.
Y ya no te digo nada si metemos strikes in the money, on the money y at the money, que menudo lio...
Resumiendo, eso que has hecho, lo he intentado hacer cuatro o 5 veces en un par de años con NVAX y no he llegado a concusión válida hasta ahora. O peor aún, la consclusión la interpreto según mis intereses. Pero bueno, yo soy bastante zoquete...

No obstante, este tema me interesa bastante,estaré atento a tus próximas intervenciones
Un saludo

SYK
Esta no sé si se puede considerar como valor del sector farmaceútico, pero tiene buena pinta , va derechita cuesta arriba. Lo malo es que está a 115,33$ .

On 6/6/2016, Stryker Corporation (NYSE:SYK) highlighted downward shift of -0.03% or -0.03 points to $113.53. The company traded a volume of 1.49 million shares over average volume of 1.4 million shares. Trailing twelve month period, the firm has earnings per share (EPS) ratio of 4.27 and price-to-earnings (P/E) ratio was noted as 26.57 for same period.

Stryker Corporation has changed +2.63% up its 50 day moving average of $110.62 and moved above +11.92% from its 200 day moving average of $101.44.

Due to negative move, the stock’s recent closing price is lower than its previous close of $113.56. Analyst’s consensus target price is measured at $116.50 for twelve month.

Actualizados los cortos:

https://divistheend.herokuapp.com/

Fraaamuuuuussss

ACHN Unica bio de mi portfolio que cerró en verde ayer, hoy acaban de presentar en congreso EHA en Dinamarca, nuevos datos positivos y especialmente interesantes tras el "fiasco" de ALXN (Soliris)
Datos de la "nueva" ACHN (digo nueva, porque las news son referentes a la plataforma FactorD, no a HepC)

Achillion Presents Interim Phase 1 Results for ACH-4471, a Novel Orally-Administered Factor D Inhibitor, at the 21st Congress of the European Hematology Association
- Results indicate up to 100% inhibition of alternative-pathway (AP) activity in hemolysis and Wieslab assays after oral dosing of ACH-4471 -
- Results support initiation of phase 1 multiple-ascending trial during the second quarter and phase 2 studies for paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy (C3G) by year-end 2016 -

NEW HAVEN, Conn., June 10, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (ACHN) today presented interim results from a phase 1 study with its novel small molecule factor D inhibitor, ACH-4471, at the 21st Congress of the European Hematology Association in Copenhagen, Denmark.

The e-poster entitled, "An Orally Administered Small Molecule Factor D Inhibitor (ACH-4471) For Treatment of PNH, C3G and Complement – Mediated Diseases: Interim Phase 1 Results In Healthy Volunteers” describes results from an ongoing phase 1 study led by Roderick B. Ellis-Pegler and Christian Schwabe of Auckland Clinical Studies Ltd, Auckland, New Zealand and a group of researchers from Achillion.

Across all four groups, ACH-4471 achieved peak plasma concentrations between 1 and 2.5 hours after oral dosing. Up to 100% inhibition of complement activity was achieved in all dose groups, and duration of inhibition was dose dependent. In addition, Group 4, which evaluated 1,200 mg of ACH-4471 given every twelve hours for 2 doses, achieved a median 99.5% inhibition (range 96 – 100%) of hemolysis at 24 hours.

"We are very encouraged by these data, which support our focus on developing potent, specific factor D inhibitor compounds, including ACH-4471, as a potentially novel approach to treating alternative pathway complement-mediated diseases such as PNH and C3G,” commented Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion. “Achieving sustained suppression of AP activity, as measured by the AP hemolysis and Wieslab assays, combined with modeling from these interim study results, suggest the potential for twice daily dosing to achieve sustained inhibition of AP activity."

The phase 1 study, initiated in February 2016, aims to assess the safety and tolerability of single ascending oral doses of ACH-4471 in healthy volunteers and to evaluate its pharmacokinetic (PK) and pharmacodynamic (PD) profile and PK/PD relationship as measured by the serum alternative pathway (AP) activity ex vivo.

In the study, 36 subjects have been dosed and evaluated. Trial participants were assigned to one of four groups:

Group 1: 200 mg, single dose (6 active + 6 placebo subjects)
Group 2: 600 mg, single dose (6 active + 2 placebo subjects)
Group 3: 1200 mg, single dose (6 active + 2 placebo subjects)
Group 4: 1200 mg x 2 doses (Q12H) (6 active + 2 placebo subjects)
For all groups, inhibition of serum AP activity was evaluated using the AP Wieslab and hemolysis assays. Blood samples were collected from days 1 through 7 to determine plasma concentrations. Trial participants were monitored through the last scheduled visit at day 28 for any adverse events.

The interim study data indicate ACH-4471 was well-tolerated at all dose levels examined with no safety trends noted. Evaluation of serum AP activity by ex vivo assessment suggests rapid inhibition of AP activity after oral dosing. Furthermore, the concentrations of Bb, the cleavage product of factor B by factor D, were determined for the assessment of the inhibitory effect of ACH-4471 on in vivo factor D activity. Bb levels were shown to decline after dosing with ACH-4471 with the lowest Bb levels observed at 16 hours post-dosing in Groups 3 and 4 and a gradual return to baseline by 48 hours after dosing.

Achillion plans to begin dosing in a phase 1 multiple-ascending dose study evaluating 14-days of dosing in healthy volunteers in June. The Company is also planning to initiate phase 2 studies of ACH-4471 in two complement-mediated diseases, PNH and C3G, by the end of 2016.

Abstracts for the 2016 Congress of the European Hematology Association are available online and can be accessed at http://www.ehaweb.org/. A reprint of the late breaking poster presentation will be available from the Resources section of the Achillion website at http://www.achillion.com.

About the Achillion Complement Factor D Platform

Achillion has leveraged its internal discovery capabilities and a novel complement-related platform to develop drug candidates that are oral inhibitors of complement factor D. Factor D is an essential serine protease involved in the complement pathway, a part of the innate immune system. Achillion's complement platform is focused on seeking to advance small molecule compounds that inhibit factor D and can potentially be used in the treatment of immune-related diseases in which complement plays a critical role. Potential indications being evaluated for these compounds include paroxysmal nocturnal hemoglobinuria (PNH), C3 Glomerulopathy (C3G), dry age-related macular degeneration (dry AMD), and chronic obstructive pulmonary disease (COPD). Achillion anticipates that its platform could play a role in addressing the needs of all PNH patients, including patients who have suboptimal response to, or fail to respond to, the currently available treatments, as well as for patients suffering from other alternative pathway complement-mediated diseases. Achillion nominated ACH-4471 for clinical development in December 2015, and initiated clinical development in February 2016.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc. (ACHN) is a science-driven, patient-focused company seeking to leverage its strengths across the continuum from discovery to commercialization in its goal of providing better treatments for people with serious diseases. The company employs a highly-disciplined discovery and development approach that has allowed it to pursue best-in-class oral antiviral therapy for chronic hepatitis C (HCV) and build a platform of potent and specific complement inhibitors. Achillion is rapidly advancing its efforts to become a fully-integrated pharmaceutical company with a goal of bringing life-saving medicines to patients with rare diseases. More information is available at http://www.achillion.com.

NVAX

No entiendo la excesiva importancia que le damos al número de cortos. Sigue habiendo muchos? Si. Es evidente.
Pero no debemos olvidar que 25 de esos 64 millones de cortos están vinculados de manera directa con las notas convertibles.
El precio cuando esta se diseñó estaba ente los 6 y los 7 dólares con el terrible comienzo de año de las bolsas mundiales por cortesía de China.
Y el precio de conversión de las notas está en los 6,81$ para unos 44 millones de acciones.
Eso debe dar mucha tranquilidad a los golfos de Citi, JPM o Piper Jaffray para satisfacer sus tejemanejes con el riesgo contenido.
Yo veo que con una subida de unos 80/90 centavos (diferencia entre mininos y máximo de esta última quincena de mayo) solo han podido cerrar 800k títulos en sus posiciones cortas.

http://stockcharts.com/h-sc/ui?s=NVAX&p=D&st=2016-05-16&en=2016-05-31&id=p88498991278

Y ahora estamos en niveles en los que ya no pueden sentirse tan cómodos porque empiezan a entrar en pérdidas en sus posiciones.
No deberíamos olvidar que para cerrar sus posiciones TIENEN QUE COMPRAR. Si para cerrar 800k han subido el precio unos 80/90 centavos, para cerrar millones y millones de titulos....

Insisto, y si, puedo ser un pesado pero lo que digo es un hecho.
Los cortos son combustible para las subidas. Eso es así. Siempre. Y sin ellos el control del precio por parte de las manos fuertes sería mucho más difícil.
Así que veamos los cortos con más perspectiva y menos pesimismo.

Ah!!!! Quiero daros un dato llamativo.

Los cortos en Celator, opada en 30$ (1,5 billones) por Jazz el pasado 31 de mayo pasaron de los 788k el 15 de enero a los 3,6 millones el 15 de mayo.
http://www.nasdaq.com/symbol/cpxx/short-interest
No uso el 31 de mayo porque ese es el día de la OPA. Pero el 31 de mayo el número estaba en 3,4 millones de cortos.
Y la cifra pasa de 1,6 millones el 15 de abril a más de 3,7 millones el 30 de ese mes.
Celator, CPXX

Y por cierto en ANAC opada por Pfizer los cortos pasaron de 4 millones el 15 de enero a casi 7 millones el 15 de mayo.

Y no, no digo que lo de Novavax sea por una OPA. Digo que el crecimiento de los cortos no es el fin del mundo y que de hecho mucha veces es el anticipo de gigantescas subidas.
No more no less.